ImVacS will return to the Marriott Long Wharf August 29- Sept. 2, 2016
Wrapping up its tenth year, ImVacS played host to a record-breaking 320+ professionals working in immunotherapies and vaccines. The 2015 event brought with it a newly added plenary keynote, given by Dr. Polly Matzinger of the NIH, that touched upon everything from adjuvants to tregs while challenging assumptions and encouraging new ways of thinking. Additional themes throughout the week included emerging indications for immunotherapies, DNA and RNA vaccines, and immunotherapy target discovery.
ImVacS 2015 Event Stats:
- 320+ Delegates from 200+ Companies
- 100 Speakers
- 25+ Posters Presented
- 20 Participating Nations
- 10 Exhibiting Companies
“Great topics and opinion sharing, always engaging and thought provoking. Very clear overview of many current trends.”
“Session quality and speakers were excellent!”
ImVacS will return to the Marriott Long Wharf once again in 2016 with the latest in immunotherapy and vaccines to ensure researchers have the information and tools they need to advance these fields. We hope to see you there!
The ImVacS Team
Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations.
The “Novel Vaccines” meeting explores how vaccine development is being innovated in order to create more efficacious vaccines, such as using Systems Biology or Reverse Vaccinology. The use of adjuvants – their safety and mode of action – will also be discussed, as will DNA vaccines, Toll-Like Receptors, and novel modes of delivery. In addition, how improved vaccines are targeting infectious diseases will be addressed and updated.